JNJ-41443532（Cat No.:I007443）is an investigational small-molecule inhibitor developed by Janssen, targeting the colony-stimulating factor-1 receptor (CSF1R), a tyrosine kinase involved in the regulation of monocyte and macrophage proliferation, survival, and differentiation. By selectively inhibiting CSF1R signaling, JNJ-41443532 modulates the tumor microenvironment and immune cell activity, showing promise in the treatment of cancers and inflammatory diseases where macrophage-driven pathology is significant. It is being studied for its potential to deplete tumor-associated macrophages (TAMs), reduce inflammation, and enhance the effectiveness of immunotherapy. Preclinical studies suggest good oral bioavailability and target specificity.